Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 150

PDF Downloaded: 32


Get Permission Bhateja, Sachdeva, Arora, Malhotra, and Malhotra: Ocular manifestations of oral mucosal lesions


Introduction

Specialized stratified epithelium derived from the ectoderm makes up the oral mucosa. An oral mucosal lesion (OML) is characterized by any unusual change influencing the oral mucosal surface coming about as a result of local pathology or auxiliary to systemic illness, including those of skin.1 The etiology of OMLs is multifactorial and they frequently cause inconvenience or agony that impedes rumination, gulping, and speech, and additionally can lead to halitosis, xerostomia, or oral dysesthesia which interferes with normal agility and slows down day to day activities.2

OMLs are identified by their location, size, color, pattern, symptoms, and distribution. Due to similar symptoms and appearances, oral cavity lesions can be difficult to diagnose and treat. Typically, histopathological results and occasionally immunohistochemistry are used to confirm a diagnosis.1 Although these lesions most frequently affect the oral cavity, they can also have peculiar ocular manifestations that often go unnoticed. It is important for any practitioner to be aware of these manifestations as they can offer important clues pertaining to the diagnosis and subsequent treatment planning of the condition.

Pemphigus Vulgaris

Loose sores accompanied by erosions seen on otherwise unaffected skin/mucosa represent hallmarks of an autoimmune condition, Pemphigus vulgaris (PV).3 Oral and mucosal lesions may present with the first sign in as many as 80% to 90% of cases. The condition usually affects the oral mucosa, however, the larynx, esophagus, anus, cervix, and vulva have also shown to be affected. Rather than tense rankles evident in cases of bullous pemphigoid, patients with PV are seen to have flaccid rankles on an erythematous base.4 The rankles may give the appearance of Nikolsky's sign (depicting the division of the epithelium with digressive strain on surface of the skin), offering a reasonably delicate however exceptionally unambiguous mark aiding in PV diagnosis.5

Ocular manifestations

Bean et al in 1975 first reported a case of ocular involvement in PV.6 Visual association is usually restricted to certain areas namely the eyelids and conjunctiva without influencing visual acuity. The most frequently reported side effects include soreness, photophobia, agony, and irritation.7 Bilateral conjunctivitis is an incessant kind of visual participation (Figure 1). Additional serious visual contribution showing up as palpebral conjunctival disintegration is additionally usually noticed and is more predominant. Bulbar conjunctivae disintegration is seldom noticed.3 Medial half of the lower eyelid might represent with lid margin erosions, which may be pathognomonic of this condition.8 A study by Akhyani M et al (2014) revealed that visual contribution was available in 16.5% PV patients with conjunctivitis being the most pervasive kind of visual inclusion (52.9%), trailed by disintegration of the palpebral conjunctiva (41.2%) and disintegration of the bulbar conjunctiva.3

Figure 1

Bilateral mild conjunctivitis seen in PV3

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/5a679ddc-2e86-42bf-ae05-f80327cf2f3c/image/6bacc84a-f3d6-4199-939e-53ddfd73426d-uimage.png

Conjunctival involvement in PV has been shown to be effectively treated with a localized intralesional triamcinolone injection as well as systemic treatment.9 Topical steroids like prednisolone acetate are typically employed for treating acute inflammation, on the other hand, cyclosporin suspension adjunct is required for chronic inflammation.10

Mucous Membrane Pemphigoid

Mucous membrane pemphigoid (MMP) refers to a persistent vesiculobullous lesion affecting the eyes principally by means of conjunctival scarring. Practically, every patient fosters oral association and individuals ranging from 61% to 80% report visual connection.11 This disorder has been seen to be bound to the eye in roughly 20% of affected individuals.12 Apart from the same, additionally affected mucous layers incorporate pharynx, nasal mucosa, larynx, genital mucosa, rectum, and esophagus.13

Ocular manifestations

MMP with visual contribution called as ocular cicatricial pemphigoid, refers to a sight-compromising sickness portraying as chronic conjunctivitis.12 The condition seldom affects one-side and can happen in seclusion or occur alongside other mucous membranes.14 Patients every now and again report with photophobia, burning, mucous release or unfamiliar sensations, while clinicians can see erythema or signs of scarring.15 Lesion progression is consistently depicted by cicatrising conjunctivitis with subepithelial fibrosis eventuating in symblepharon advancement and fornix foreshortening, typically impacting the inferior fornix initially.16 Average canthal scarring along with plica and caruncle loss has in like manner been advanced as an early indication.17 Reports of the scarring framework annihilating goblet cells, lacrimal organ ductules, and meibomian gland orifices inciting dry eye ailment have similarly been recorded.18 Advanced ailment contains lagophthalmos, trichiasis, ectropions, entropions, and corneal ulceration. 19 In case of not being dissected or treated early, development to extreme OSD leading to vision loss has been represented to occur in 33% of affected individuals.14 To examine this condition in its starting stages, ophthalmologists should search for unpretentious inferior forniceal pressure and symblephara, which can be perceived when the lower eyelid is pulled down while the patient gazes upward (Figure 2). Ocular cicatricial MMP changes can be staged using a variety of scoring systems. Organizing system given by Foster has been used comprehensively as a disease development marker in visual MMP (Table 1).20 In 1992, Tauber et al. cited these systems' individual insensitivity and suggested a combined format (Table 2).21

Figure 2

Inferior fornix shortening and bulbar and palpebral conjunctival fusion in mucous membrane pemphigoid

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/5a679ddc-2e86-42bf-ae05-f80327cf2f3c/image/8a46df65-e079-433a-9926-29423090d71d-uimage.png

A multidisciplinary approach is much of the time essential in the administration of MMP. Triamcinolone acetonide and other effective corticosteroids can be utilized to treat some intense and visual injuries in the early phase.22 Topical retinoids may help treat posterior lid margin conjunctival keratinization. The time when moderate conjunctival cicatrization is noticed, subconjunctival mitomycin C or steroid imbuement may be effective.23 Visual surface reproduction, incorporating cautious correction of eyelid contortions or eyelash expulsion for trichiasis may be expected to achieve visual surface tranquility. Mechanical epilation, cryotherapy, bipolar electrolysis, radiofrequency removal, or laser removal can be generally used to eliminate atypical lashes, which is important for forestalling corneal ulcers or disintegrations. Punctal hindrance can be helpful in overseeing dry eye associated with MMP.4

Table 1

Foster staging system

Stage

Characteristics

I

Subconjunctival scarring and fibrosis

II

Fornix foreshortening of any degree

III

Presence of symblepharon, any degree

IV

Ankyloblepharon, frozen globe

Table 2

Tauber staging system

Stage

Characteristics

I

Subconjunctival scarring and fibrosis

II

a. 0–25% loss of inferior fornix depth

b. 25–50% loss of inferior fornix depth

c. 50–75% loss of inferior fornix depth

d. 75–100% loss of inferior fornix depth

III

a. 0–25% horizontal involvement of symblephara

b. 25–50% horizontal involvement of symblephara

c. 50–75% horizontal involvement of symblephara

d. 75–100% horizontal involvement of symblephara

n. Number of symblephara countable

IV

Ankyloblepharon, frozen globe

Paraneoplastic Pemphigus

Neoplasms either benign or malignant, are associated with paraneoplastic pemphigus (PNP). Non-Hodgkin lymphoma, chronic lymphocytic leukemia, Castleman's disease, and thymomas are the most frequently associated neoplasms.19 Affected individuals report with erosive and rankling skin and mucosal sores. Mucous layer association happens in nearly every individual suffering from this condition. Mucosal involvement is seen in many body parts namely the lips, gingival, buccal, and lingual mucosa, nasopharynx, oropharynx, nasal septum, hypopharynx, larynx, tracheobronchial mucosa, esophagus, and epiglottis. Cutaneous lesions typically appear several days to months after mucous membrane lesions.24

Ocular manifestations

Ocular symptoms of PNP comprise of red discoloration, discomfort, irritation, mucus discharge and vision deterioration. Patients could report a reciprocal cicatrizing conjunctivitis alongside fornices reduction and symblepharon development. Apart from these, thickening of the eyelid edge, conjunctival deterioration, pseudomembranous conjunctivitis, and corneal epithelial deformations may also be seen. Decrease in baseline tear secretion may be seen in Schirmer tear production test.25 In severe cases, two-sided corneal melting may also occur. 26

When seeing cases of PNP, careful and prompt treatment can assist with forestalling vision misfortune and visual deficiency by monitoring for ocular surface complications. Notwithstanding fundamental immunosuppressive treatment and treatment of the basic harm, visual treatment might incorporate the utilization of surface corticosteroid drops, 10% N-acetylcysteine, sodium hyaluronate as well as successive additive-free artificial tears. Amniotic membrane grafting as a surgical treatment might be significant while examining instances with wide conjunctival scarring & fornice deficiency.27

Lichen Planus

Lichen planus (LP) refers to immune system disorder predominantly influencing the skin and mucous membranes.28 LP comprises of different cutaneous, mucosal, & subungual appearances unaccompanied or related to each other. The assessed recurrence of mucosal affiliation ranges between 30-70%.29 Oral mucosae is the most notable region of contribution seen in mucosal LP. This is followed by genitalia, esophageal and nasopharyngeal association.30 Ear as well as the visual surface are various locales of association.28 The course of the illness is an extreme disturbance of the skin or mucosal tissues giving rise to injuries and crumbling. The infection forms into a persistent harmless course set apart by fibrous bands and scarring after a self-restricting irritation. 30

Ocular manifestations

In 1904, Gaucher and Druelle described the first case of ocular surface involvement in the form of white conjunctival streaks.28 LP usually occurs in visual structures, yet just once in a blue moon, the visual contribution is for the most part joined with cutaneous or oral signs.31 The disease can cause cicatricial conjunctivitis or eyelid and corneal involvement. Conjunctival inclusion can prompt blepharitis, keratitis, symblepharon, corneal ulceration, and lingering visual debilitation.32 LP can also cause epiphora and pathologies in the lacrimal canal.33

First-line medications incorporate topical corticosteroids and cyclosporin. Those patients not unresponsive to topical medicines might benefit with systemic treatment with corticosteroids and other immunosuppressive agents, for example cyclosporin, azathioprine, or mycophenolate mofetil.34 Effective treatment of patients with detached conjunctival lichen planus utilizing skin cyclosporin A 2% in olive oil has likewise been reported.35

Linear Immunoglobulin A Disease

An uncommon condition known as linear immunoglobulin A disease(LAD) is described by the presence of circulating immune system antibodies that focus on the epithelial basement membrane zone.4 Patients who are impacted normally present with a delayed prodrome of cutaneous burning or pruritus before lesion development. Commonly, the erythematous skin area is encircled by annular tense bullae that look like a "string of pearls" or "cluster of jewels". Wounds routinely incorporate the perioral region, perineum, and extremities. Moreover, mucous film affiliation is found in adults, with oral, genital, and conjunctival bruises that can bring about scarring.36

Ocular manifestations

Dry eye, the feeling of an unfamiliar body in the eye, conjunctival scarring with trichiasis, entropion, corneal opacification, neovascularization, and the possibility for visual impairment are the ophthalmologic signs.37 This pathology can be hard to distinguish from other scarring infections like visual cicatricial pemphigoid. To confirm the diagnosis, a skin biopsy ought to show stores of IgA in an immediate dispersal over the intersection among dermis and epidermis. All LAD patients ought to have their eyes examined because ocular involvement is common and may not cause symptoms (about 50% of LAD patients).38

A short oral steroid course might be valuable in determined instances of medication prompted LAD. Drug-initiated cases ordinarily resolve rapidly after the culpable prescription is recognized and stopped. The mucosal and cutaneous lesions can be treated locally, but bullae don't usually require anything more than clean dressings, and infected lesions can be treated with topical antibacterials like mupirocin. The usage of dapsone or sulfapyridine is productive in a large portion of cases, bringing about observable reaction to treatment soon. Prednisone, dicloxacillin, sulfamethoxypyridazine, and colchicine are examples of adjunct therapies that may be beneficial for disease that has been treated for more than a few weeks.4

Epidermolysis Bullosa Acquisita

The most exceptional of the vesiculobullous immune system conditions is Epidermolysis bullosa acquisita (EBA). Around 9.6% of EBA cases have been related with different circumstances like rheumatoid joint inflammation, Crohn's ailment, ulcerative colitis, psoriasis, and thyroiditis. Rankles and bullae on the skin and mucous films are the signs of EBA. Visual, genital, esophageal, tracheal, and anal mucosae are the following most commonly impacted mucosal locales. Also oral sores are alluded to as inescapable, pain causing rankles, disintegrations, and scarring that can happen on any surface of the oral mucosa.39

Ocular manifestations

Corneal disintegrations or rankles, corneal scarring, symblepharon, blepharitis, ectropion, lacrimal duct obstruction, impeded vision, and visual impairment are among the visual intricacies of EBA that have been accounted for.40 The frequency with which these complications occur varies between the various subtypes. The most generally perceived sort of epidermolysis bullosa related with visual ensnarements is the dystrophic type, which every now and again incorporates the conjunctiva, achieving scarring and symblepharon development. 41 Visual and tracheal contribution might prompt visual impairment and hazardous respiratory complications due to scarring.39 The Epidermolysis Bullosa Sickness Action and Scarring Record (EBDASI), made in 2014, was the primary crucial gadget to consolidate a subsection scoring visual consideration with partition between illness 'action' and 'harm' (Table 3). 42

Table 3

Ocular scoring in the Epidermolysis Bullosa Disease Activity and Scarring Index

Activity

Damage

Erosions/ blisters/ erythema/ mucosal atrophy/ fissures/ stenosis

Score

Lesions

Score (0 = absent) (2 = present)

Absent

0

Ectropion

1 lesion

1

Symblepharon

2–3 lesions

2

Visible corneal opacity

> 3 lesions or 2 lesions > 2 cm

5

Entire area

10

Total activity score

/10

Total damage score

/6

Systemic corticosteroids are used as the principal line of treatment for this condition. Amniotic layers can be utilized to heal harmed mucosal surfaces and remake corneal and conjunctival surfaces that are damaged in different conditions that disturb the visual surface. 43 This tissue works with epithelialization and diminishes aggravation, vascularization, and scarring. 44 Symblepharon lysis and lamellar keratectomy are the suggested remedies for individuals with symblepharon and corneal obscurity. Rituximab and high-portion intravenous Immunoglobulin have demonstrated to be compelling in EBA therapy, especially in obstinate cases. 43

Erythema Multiforme

Erythema multiforme (EM) is a class IV cytotoxic reaction generally focusing on keratinocytes, demonstrating commendable designated sores.45 EM comprises of two varieties, erythema multiforme major (EMM) and erythema multiforme minor (EMm). EMM and EMm are both depicted by cutaneous wounds impacting <10% of the body surface. The wounds present with rankled or necrotic focuses, included by an erythematous ring. They can be intense and generally resolve with scarring. Oral mucosa (70%) is the most notable mucosal site included. Be that as it may, the eyes, genitalia, upper respiratory area, and pharyngeal mucosa could likewise be impacted. 46

Ocular manifestations

Visual contribution in EM minor is ordinarily gentle and may appear as red conjunctivae, chemosis, and lacrimation (Figure 3).47 As per study conducted by Chang YS, the underlying visual appearances of acute EM incorporate eyelid edema, erythema, crusting, and conjunctival hyperemia. These disclosures were tracked down in more than 90% patients with visual commitment. Residual 8.5 percent had more serious conjunctival aggravation (chemosis, development of the conjunctival layer, and pseudomembrane), and 18.8 percent had corneal contribution.48

Figure 3

Eye conjunctivitis seen in EM

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/5a679ddc-2e86-42bf-ae05-f80327cf2f3c/image/17004d4e-da01-4abb-b6e3-3a8c4b4e0f0b-uimage.png

Ointments hydrate the visual surface and flush away inflammatory substances. Effective anti-infection agents have displayed to diminish the risk of visual disease. Surgery is highlighted towards adjusting the essential imperfections or distortions. Lysis of symblepharon and conjunctival recession may be embraced to remake the conjunctival fornix. There are a number of ways to correct cicatricial entropion and ectropion, including using a skin or mucosal graft.48

Leukoplakia

Leukoplakia is a condition referring to a white patch/plaque that for the most part is seen on mucus membranes of the mouth.49 The specific reason for leukoplakia is obscure, however smoking, drinking a lot of liquor, irritating food substances, and persevering friction — for example, because of improperly fitting dentures or spiked teeth — might be connected to it. The oral mucus membrane, vocal strings, digestive tract, or mucosal area of the urinary tract and private parts can be in every way impacted by plaque.50

Ocular manifestations

Leukoplakia can likewise happen on corneal surface, at times looking like a vernal keratoconjunctivitis-like calcium deposit or else mucous patch. This could be a direct result of entropion, which leads to corneal disturbance. Limbus region can also be affected by this condition and can extend to the cornea as well as bulbar conjunctiva (figure 4).49 Leukoplakia of the cornea can likewise be seen as purported unique finger impression epithelial lines.51

Figure 4

Leukoplakia on the bulbar conjunctiva

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/5a679ddc-2e86-42bf-ae05-f80327cf2f3c/image/c88a86a8-5529-4b59-b972-80ff36c74404-uimage.png

Candidiasis

Candida spp. are the microorganisms that cause the most invasive fungal infections.52 Perhaps of the most widely recognized fungal infections that influence the oral mucosa is oral candidiasis. The yeast Candida albicans, which is one of the components of normal oral microflora, is responsible for these lesions.53 Similar to the oral cavity, C. albicans colonizes the gastrointestinal and reproductive tracts asymptomatically of otherwise healthy individuals.54 Furthermore, candida sp. represent one of the well-known reasons for diseases in the circulatory system and have the potential to spread to any body part and can affect the heart, lungs, brain, kidneys, eyes, liver, and spleen.55

Ocular manifestations

Ocular candidiasis is a critical complication of candidemia. Endophthalmitis and chorioretinitis, both of which result in significant visual loss, can be brought on by Candidaemia. Candida endophthalmitis is brought about by hematogenous seeding of the choroid & retina by means of little vessels. Organic entities subsequently, at that point, multiply, causing both central aggravation and restricted abscess development. Resulting about spread to the vitreous body could lead to endophthalmitis and retinal separation. Subacute beginning of obscured vision accompanied along with low-rate torment, photophobia, and injection are typical side effects. Endophthalmitis is set apart by ''cushion balls,'' or vitreous abscesses. Hypopyon, scleritis, alongside association of the third cranial nerve may also be noticed in endophthalmitis.56

Visual candidiasis can be dealt with the systemic and topical antifungal treatment, or with intravitreal imbuement of an antifungal agent, now and again alongside vitrectomy. Fluconazole and voriconazole, on the other hand, reach vitreous concentrations that range from 25% to 100% of their serum concentrations, while systemic amphotericin B and echinocandins don't infiltrate all the way into the vitreous humor.57

Conclusion

Ocular involvement in OMLs is well documented in the literature. Management of ocular complications might often require a collaborative effort among different specialists. Hence, a thorough knowledge regarding the ocular manifestations of oral mucosal lesions is a prerequisite for every specialist. The early diagnosis and treatment using established immunoregulatory agents, as well as the development of new ones, should be prioritized, as it aids in prevention of these diseases' morbidities.

Source of Funding

None.

Conflict of Interest

None.

References

1 

VR Jain RS Mahajan SS Rathi VV Biyani KR Ninama YS Marfatia Oral Mucosal Lesions - A Study of 369 CasesIndian Dermatol Online J202314221320

2 

R Goyal S Jadia L Jain C Agarawal A Clinical Study of Oral Mucosal Lesions in Patients Visiting a Tertiary Care Centre in Central IndiaIndian J Otolaryngol Head Neck Surg20166844136

3 

M Akhyani A Keshtkar-Jafari C Chams-Davatchi V Lajevardi S Beigi N Aghazadeh Ocular involvement in pemphigus vulgarisJ Dermatol201441761821

4 

S Feizi D Roshandel Ocular Manifestations and Management of Autoimmune Bullous DiseasesJ Ophthalmic Vis Res2019142195210

5 

SJ Challacombe J Setterfield P Shirlaw K Harman C Scully MM Black Immunodiagnosis of pemphigus and mucous membrane pemphigoidActa Odontol Scand200159422634

6 

SF Bean K Halubar RB Gillett Pemphigus involving the eyesArch Dermatol19751111114846

7 

YJ Daoud R Cervantes CS Foster AR Ahmed Ocular pemphigusJ Am Acad Dermatol200553458590

8 

C Laforest SC Huilgol R Casson D Selva I Leibovitch Autoimmune bullous diseases: ocular manifestations and managementDrugs20056513176779

9 

EB Turkoglu S Alan Intralesional triamcinolone acetonide for refractory ocular pemphigus vulgaris: A case seriesJ Fr Ophtalmol20153892079

10 

O Memar S Jabbehdari B Caughlin AR Djalilian Ocular surface involvement in pemphigus vulgaris: An interdisciplinary reviewOcul Surf2020181406

11 

ME Foster FF Nally Benign mucous membrane pemphigoid (cicatricial mucosal pemphigoid): a reconsiderationOral Surg Oral Med Oral Pathol1977445697705

12 

LS Chan AR Ahmed GJ Anhalt W Bernauer KD Cooper MJ Elder The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicatorsArch Dermatol200213833709

13 

JE Thorne GJ Anhalt DA Jabs Mucous membrane pemphigoid and pseudopemphigoidOphthalmology200411114552

14 

LS Chan Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)Clin Dermatol2012301347

15 

P Sanfilippo G Lee Ocular cicatricial pemphigoidClin Exp Optom20038614750

16 

C Camisa DM Meisler Immunobullous diseases with ocular involvementDermatol Clin199210355570

17 

JK Dart The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years onEye (Lond)201631230132

18 

BWH Lee JCK Tan M Radjenovic MT Coroneo DF Murrell A review of scoring systems for ocular involvement in chronic cutaneous bullous diseasesOrphanet J Rare Dis201813183

19 

KC Broussard TG Leung A Moradi JE Thorne JD Fine Autoimmune bullous diseases with skin and eye involvement: Cicatricial pemphigoid, pemphigus vulgaris, and pemphigus paraneoplasticaClin Dermatol201634220513

20 

CS Foster Cicatricial pemphigoidTrans Am Ophthalmol Soc198684527663

21 

J Tauber N Jabbur CS Foster Improved detection of disease progression in ocular cicatricial pemphigoidCornea199211544651

22 

S Silverman M Gorsky F Lozada-Nur A Liu Oral mucous membrane pemphigoid. A study of sixty-five patientsOral Surg Oral Med Oral Pathol19866132337

23 

JC Sánchez NL Ferrando MG Largacha FGd Valle MJOd Torre Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoidArch Soc Esp Oftalmol20027795016

24 

JW Frew DF Murrell Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome)Dermatol Clin201129460712

25 

PM Tam LL Cheng AL Young PT Lam Paraneoplastic pemphigus: an uncommon cause of chronic cicatrising conjunctivitisBMJ Case Rep20092009 10.1136/bcr.12.2008.1306

26 

T Anan F Shimizu Y Hatano O Okamoto K Katagiri S Fujiwara Paraneoplastic pemphigus associated with corneal perforation and cutaneous alternariosis: a case report and review of cases treated with rituximabJ Dermatol2011381110849

27 

SJ Meyers GA Varley DM Meisler C Camisa AH Wander Conjunctival involvement in paraneoplastic pemphigusAm J Ophthalmol199211456214

28 

M Mohebbi M Mirghorbani AB Afshan M Towfighi Lichen Planus in Ocular Surface: Major Presentations and TreatmentsOcul Immunol Inflamm201927698794

29 

JS Lehman MM Tollefson LE Gibson Lichen planusInt J Dermatol200948768294

30 

G Wagner C Rose MM Sachse Clinical variants of lichen planusJ Dtsch Dermatol Ges201311430919

31 

E Ozlu K Teberik Evaluation of ocular findings in patients with lichen planusPostepy Dermatol Alergol201936326771

32 

YYM Huang CM Wang S Potenziani S Hsu Lichen planus of the eyelids: a case report and review of the literatureDermatol Online J201723213030/qt1c04h08s

33 

NK Webber JF Setterfield FM Lewis SM Neill Lacrimal canalicular duct scarring in patients with lichen planusArch Dermatol201214822247

34 

ER Muñoz ME Martínez-Escala N Juanpere J Armentia RM Pujol JE Herrero-González Isolated conjunctival lichen planus: a diagnostic challengeArch Dermatol201114744657

35 

M Pakravan TR Klesert EK Akpek Isolated lichen planus of the conjunctivaBr J Ophthalmol2006901013256

36 

S Chaudhari N Mobini Linear IgA Bullous Dermatosis: A Rare Clinicopathologic Entity with an Unusual PresentationJ Clin Aesthet Dermatol2015810436

37 

C Ramos-Castellón G Ortiz-Nieva F Fresán L Villalvazo Y Garfias A Navas Ocular involvement and blindness secondary to linear IgA dermatosisJ Ophthalmol20102010280396

38 

EA Aultbrinker MB Starr ED Donnenfeld Linear IgA disease. The ocular manifestationsOphthalmology19889533403

39 

SA Alramadhan MN Islam Vesiculobullous Lesions of the Oral CavityOral Maxillofac Surg Clin North Am202335220317

40 

JD Fine LB Johnson M Weiner A Stein S Cash J Deleoz Eye involvement in inherited epidermolysis bullosa: experience of the National Epidermolysis Bullosa RegistryAm J Ophthalmol2004138225462

41 

R Altan-Yaycioglu YA Akova S Oto Amniotic membrane transplantation for treatment of symblepharon in a patient with recessive dystrophic epidermolysis bullosaCornea20062589713

42 

CC Loh J Kim JC Su BS Daniel SS Venugopal LM Rhodes Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)J Am Acad Dermatol20147018997

43 

M Kasperkiewicz CD Sadik K Bieber SM Ibrahim RA Manz E Schmidt Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic OptionsJ Invest Dermatol201613612433

44 

S Shimmura J Shimazaki Y Ohashi K Tsubota Antiinflammatory effects of amniotic membrane transplantation in ocular surface disordersCornea200120440813

45 

B Senger SA Memar A Ahmann JJ Houser L Doughty-Mcdonald Dermatologic and Ophthalmologic Treatment of Erythema Multiforme Major: A Case ReportCureus20211312e20854

46 

O Sokumbi DA Wetter Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologistInt J Dermatol2012518889902

47 

S Jain MK Rathore PC Dwivedi E Tirkey Corneal lesions in erythema multiforme minor--are systemic steroids indicated?Indian J Ophthalmol201058655960

48 

YS Chang FC Huang SH Tseng CK Hsu CL Ho HM Sheu Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and managementCornea20072621239

49 

A Zdebik N Zdebik M Fischer Ocular manifestations of skin diseases with pathological keratinization abnormalitiesPostepy Dermatol Alergol20213821420

50 

K Hirano M Koide Y Mizoguchi Y Osakabe KA Sasaki Unilateral corneal leukoplakia without limbal involvementInt Med Case Rep J201581036

51 

M Busin M Spitznas P Brauweiler Leukoplakia of the cornea presenting as fingerprint epithelial lines: a case reportInt Ophthalmol1991155299301

52 

S Antinori L Milazzo S Sollima M Galli M Corbellino Candidemia and invasive candidiasis in adults: A narrative reviewEur J Intern Med201634218

53 

A Singh R Verma A Murari A Agrawal Oral candidiasis: An overviewJ Oral Maxillofac Pathol2014181815

54 

T Vila AS Sultan D Montelongo-Jauregui MA Jabra-Rizk Oral Candidiasis: A Disease of OpportunityJ Fungi (Basel)2020615

55 

J L Fierro P A Prasad B T Fisher J S Gerber S E Coffin T J Walsh T E Zaoutis Ocular manifestations of candidemia in childrenPediatr Infect Dis J20133218490

56 

CP Shah J Mckey MJ Spirn J Maguire Ocular candidiasis: a reviewBr J Ophthalmol20089244668

57 

AMLO Lashof A Rothova JD Sobel M Ruhnke PG Pappas C Viscoli Ocular manifestations of candidemiaClin Infect Dis20115332628



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Review Article


Article page

627-633


Authors Details

Sumit Bhateja*, Akshat Sachdeva, Geetika Arora, Vaibhav Malhotra, Taniya Malhotra


Article History

Received : 01-09-2023

Accepted : 18-10-2023


Article Metrics


View Article As

 


Downlaod Files